A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma.
Advanced disease
Chemotherapy
Inflammation
Intrahepatic cholangiocellular carcinoma
Prognosis
Systemic-inflammatory response parameters
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
06
09
2022
accepted:
14
10
2022
medline:
19
7
2023
pubmed:
6
11
2022
entrez:
5
11
2022
Statut:
ppublish
Résumé
Systemic-inflammatory response parameters (SIR) are known prognostic markers in different tumour entities, but have not been evaluated in patients with iCCA treated with systemic chemotherapy. Therefore, we evaluated the impact of different SIR markers on the clinical course of patients with advanced iCCA treated at our center. SIR markers were retrospectively evaluated in 219 patients with iCCA at the West-German-Cancer-Center Essen from 2014 to 2019. Markers included neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), CRP, and the modified Glasgow-Prognostic-Score (mGPS), which were correlated with clinico-pathological findings, response to chemotherapy (ORR), progression-free (PFS) and overall survival (OS) using Kaplan-Meier analyses, and Cox proportional models. Median overall survival (OS) of the entire cohort was 14.8 months (95% CI 11.2-24.4). Median disease-free survival (DFS) in 81 patients undergoing resection was 12.3 months (95% CI 9.7-23.1). The median OS from start of palliative CTX (OS Inflammatory markers associate with inferior survival outcomes in patients with iCCA. A simple SIS may guide treatment decisions in patients treated with systemic chemotherapy.
Identifiants
pubmed: 36334155
doi: 10.1007/s00432-022-04424-0
pii: 10.1007/s00432-022-04424-0
pmc: PMC10349723
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5085-5094Informations de copyright
© 2022. The Author(s).
Références
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21:796–807
doi: 10.1016/S1470-2045(20)30157-1
pubmed: 32416072
pmcid: 7523268
Blechacz B (2017) Cholangiocarcinoma: current knowledge and new developments. Gut Liver 11:13–26
doi: 10.5009/gnl15568
pubmed: 27928095
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Kassambara A, Kosinski M, Biecek P (2017) Survminer: survival analysis and visualization. https://rpkgs.datanovia.com/survminer/index.html (Online-Publication)
Lamarca A, Hubner RA, David Ryder W, Valle JW (2014) Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 25:2328–2338
doi: 10.1093/annonc/mdu162
pubmed: 24769639
Lamarca A, Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, Manoharan P, Palmer D, Bridgewater J, Valle JW (2020) Advanced Intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02 and -03 clinical trials. J Natl Cancer Inst 112:200–210
pubmed: 31077311
Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K et al (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22:690–701
doi: 10.1016/S1470-2045(21)00027-9
pubmed: 33798493
pmcid: 8082275
Lin J, Fang T, Zhu M, Xu X, Zhang J, Zheng S, Jing C, Zhang M, Liu B, Zhang B (2019) Comparative performance of inflammation-based prognostic scores in patients operated for intrahepatic cholangiocarcinoma. Cancer Manag Res 11:9107–9119
doi: 10.2147/CMAR.S198959
pubmed: 31802940
pmcid: 6831984
Markus M, Abendroth A, Noureddine R, Paul A, Breitenbuecher S, Virchow I, Schmid KW, Markus P, Schumacher B, Wiesweg M et al (2021) Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy. J Cancer Res Clin Oncol 147:579–591
doi: 10.1007/s00432-020-03361-0
pubmed: 32839836
Massarweh NN, El-Serag HB (2017) Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 24:1073274817729245–1073274817729245
doi: 10.1177/1073274817729245
pubmed: 28975830
pmcid: 5937247
McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, Min T, Amir E, Knox JJ (2014) Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer 50:1581–1589
doi: 10.1016/j.ejca.2014.02.015
pubmed: 24630393
Oh D-Y, He AR, Qin S, Chen L-T, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Lee MA, Kitano M et al (2022) A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol 40:378–378
doi: 10.1200/JCO.2022.40.4_suppl.378
Okano N, Kasuga A, Kawai K, Yamauchi Y, Kobayashi T, Naruge D, Nagashima F, Furuse J (2018) The modified Glasgow prognostic score in patients with gemcitabine-refractory biliary tract cancer. Anticancer Res 38:1755–1761
pubmed: 29491113
Palmer WC, Patel T (2012) Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 57:69–76
doi: 10.1016/j.jhep.2012.02.022
pubmed: 22420979
pmcid: 3804834
Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20:663–673
doi: 10.1016/S1470-2045(18)30915-X
pubmed: 30922733
Proctor MJ, Morrison DS, Talwar D, Balmer SM, O’Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow inflammation outcome study. Br J Cancer 104:726–734
doi: 10.1038/sj.bjc.6606087
pubmed: 21266974
pmcid: 3049591
Razumilava N, Gores GJ (2014) Cholangiocarcinoma. Lancet 383:2168–2179
doi: 10.1016/S0140-6736(13)61903-0
pubmed: 24581682
pmcid: 4069226
R Core Team (2018) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/ (Online-Publication)
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15:95–111
doi: 10.1038/nrclinonc.2017.157
pubmed: 28994423
Rizzo A, Ricci AD, Tober N, Nigro MC, Mosca M, Palloni A, Abbati F, Frega G, De Lorenzo S, Tavolari S et al (2020) Second-line treatment in advanced biliary tract cancer: today and tomorrow. Anticancer Res 40:3013–3030
doi: 10.21873/anticanres.14282
pubmed: 32487595
Robert-Koch Institut (2019) Krebs in Deutschland für 2015/2016. 12. Auflage
Schweitzer N, Fischer M, Kirstein MM, Berhane S, Kottas M, Sinn M, Gonzalez-Carmona MA, Balta Z, Weismüller TJ, Strassburg CP et al (2017) Risk estimation for biliary tract cancer: development and validation of a prognostic score. Liver Int 37:1852–1860
doi: 10.1111/liv.13517
pubmed: 28695669
Therneau T (2022) A Package for Survival Analysis in R. R package version 3.4-0. https://CRAN.R-project.org/package=survival (Online-Publication)
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New Engl J Med 362:1273–1281
doi: 10.1056/NEJMoa0908721
pubmed: 20375404
Vogel A, Wenzel P, Folprecht G, Schütt P, Wege H, Kretzschmar A, Jacobasch L, Ziegenhagen N, Boeck S, Kanzler S et al (2022) Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC–AIO-HEP-0116). Ann Oncol 33(Suppl_7):S19–S26. https://doi.org/10.1016/annonc/annonc1036
doi: 10.1016/annonc/annonc1036
Wickham H (2016) ggplot2: elegant graphics for data analysis. Springer-Verlag, New York
doi: 10.1007/978-3-319-24277-4
Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Grolemund G, Hayes A, Henry L, Hester J et al (2019) Welcome to the tidyverse. J Open Source Softw 4:1686
doi: 10.21105/joss.01686
Yoo C, Kim K-P, Kim I, Kang MJ, Cheon J, Kang BW, Ryu H, Jeong JH, Lee JS, Kim KW et al (2021) Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): multicenter comparative randomized phase 2b study (NIFTY). J Clin Oncol 39:4006–4006
doi: 10.1200/JCO.2021.39.15_suppl.4006